Skip to main content
Premium Trial:

Request an Annual Quote

GeneGo Gets NCI SBIR Grant for Translational Research Platform

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – GeneGo today said that the National Cancer Institute has awarded the firm a Phase II Small Business Innovation Research grant to fund further development of an analytical platform for translational research and data analysis in oncology.

Specifically, the NCI funding will support the MetaMiner (Oncology) project being run by GeneGo in collaboration with researchers from Harvard medical School, Johns Hopkins University, the Translational Genomics Research Institute, the Van Andel Research Institute, and several global pharmaceutical firms. GeneGo's MetaMiner platform combines disease reconstruction of multiple cancers, an 'omics data repository, and statistical tools based on pathway descriptors, said GeneGo.

The St. Joseph, Mich.-based firm did not disclose the amount of the grant, but under the NCI's Phase II SBIR program, companies may apply for a grant of up to $750,000 to fund two years of R&D.

"Over the last two years, we have created a general framework for disease reconstruction (causal disease models) and annotated many thousands of 'causative' links between genes, perturbed pathways, and seven different cancers," GeneGo CEO Yuri Nikolsky said in a statement. "We see target discovery, translational cancer research, and personalized diagnostics as the top application areas for MetaMiner (Oncology)."

The Scan

WHO Seeks Booster Pause

According to CNN, the World Health Organization is calling for a moratorium on administering SARS-CoV-2 vaccine boosters until more of the world has received initial doses.

For Those Long Legs

With its genome sequence and subsequent RNAi analyses, researchers have examined the genes that give long legs to daddy longlegs, New Scientist says.

September Plans

The New York Times reports that the US Food and Drug Administration is aiming for early September for full approval of the Pfizer-BioNTech SARS-CoV-2 vaccine.

Nucleic Acids Research Papers on Targeting DNA Damage Response, TSMiner, VarSAn

In Nucleic Acids Research this week: genetic changes affecting DNA damage response inhibitor response, "time-series miner" approach, and more.